8 recruiting, 1 completed, 1 enrolling by invitation, 1 not yet recruiting. 5 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Recruiting 3, Completed 1, Not yet recruiting 1 |
| Phase 3 | 2 | Recruiting 2 |
| Early Phase 1 | 1 | Enrolling by invitation 1 |
| Not applicable | 1 | Terminated 1 |
Follow Muscle Invasive Bladder Urothelial Carcinoma: new trials by email Literature Review of Muscle Invasive Bladder Urothelial Carcinoma trials Research Report on Muscle Invasive Bladder Urothelial Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Neoadjuvant Intravesical Nadofaragene Firadenovec With Gemcitabine, Cisplatin and Durvalumab for the Treatment of Muscle Invasive Bladder Cancer, TRIFECTA Trial Nadofaragene Firadenovec, Durvalumab, Gemcitabine - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Not yet recruiting | University of Washington | 33 | 2026-12-01 | 2026-10-26 |
| Tumor-informed ctDNA in Muscle-invasive Bladder Cancer for Evaluation of Residual/Recurrent Disease - the TiMBER Trial Non-Interventional Study - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Recruiting | OHSU Knight Cancer Institute | 100 | 2026-06-29 | 2026-08-14 | |
| Combining Immunotherapy and Radiation Therapy to Help Patients Avoid Bladder Removal After Treatment Shrinks Muscle Invasive Bladder Cancer, BRIGHT Trial Biospecimen Collection, Computed Tomography, Cystoscopy - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 2 | Recruiting | National Cancer Institute (NCI) | 111 | 2025-11-25 | 2026-10-30 |
| Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study Biospecimen Collection, Cisplatin, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Stage II Bladder Cancer AJCC v8 | Phase 3 | Recruiting | NRG Oncology | 486 | 2025-10-07 | 2026-10-23 |
| Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer Enfortumab vedotin, Pembrolizumab - Muscle Invasive Bladder Urothelial Carcinoma | Phase 2 | Recruiting | Matthew Galsky | 75 | 2025-04-07 | 2026-08-05 |
| Pan-tumor MRD Study blood and tissue samples - Muscle Invasive Bladder Urothelial Carcinoma, Esophageal Cancer | Recruiting | Paradigm Health | 1350 | 2025-01-08 | 2026-09-24 | |
| Increasing Pre-Surgical Identification of Muscle Invasive Tumor Evaluations Prior to Planned Cystectomy (INSITE) Urothelial Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma | Recruiting | Fox Chase Cancer Center | 92 | 2024-08-13 | 2025-10-31 | |
| Drug Screening Using IMD in Bladder Cancer Implantable Micro-Device, Methotrexate, Carboplatin - Muscle Invasive Bladder Urothelial Carcinoma | Early Phase 1 | Enrolling by invitation | Brigham and Women's Hospital | 18 | 2024-06-14 | 2026-05-18 |
| Surveillance of the Genetic Signature in Circulating Tumor DNA for Guiding Adjuvant Chemotherapy in Urothelial Carcinoma gemcitabine, Cisplatin - Muscle Invasive Bladder Urothelial Carcinoma, Muscle-Invasive Bladder Carcinoma | Phase 2 | Completed | Yung NA | 15 | 2024-02-02 | 2026-10-28 |
| Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study Biospecimen Collection, cfDNA or ctDNA Measurement, Computed Tomography - Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma | Phase 2 / Phase 3 | Recruiting | National Cancer Institute (NCI) | 992 | 2024-02-02 | 2026-10-29 |
| Daily Online Adaptive Short-Course Radiation Therapy and Concurrent Chemotherapy for Muscle-Invasive Bladder Cancer Daily Adaptive External Beam Radiation Therapy - Muscle Invasive Bladder Urothelial Carcinoma | Not applicable | Terminated | Varian, a Siemens Healthineers Company | 2 | 2023-02-02 | 2026-04-21 |
| Study on the Quality of Life and Pathological State in Patients Who Underwent Radical Cystectomy Radical Cystectomy - Muscle-Invasive Bladder Carcinoma, Muscle Invasive Bladder Urothelial Carcinoma | Recruiting | IRCCS San Raffaele | 4000 | 2013-02-04 | 2023-12-14 |
Urinary Bladder Neoplasms (5) · Adenocarcinoma (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Transitional Cell (1) · Disease Progression (1) · Esophageal Neoplasms (1) · Melanoma (1)
Neoplasms (7) · Neoplasms by Site (6) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Male Urogenital Diseases (5) · Urinary Bladder Diseases (5) · Urogenital Diseases (5) · Urogenital Neoplasms (5) · Urologic Diseases (5) · Urologic Neoplasms (5) · Carcinoma (2) · Neoplasms by Histologic Type (2) · Neoplasms, Glandular and Epithelial (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1)
Cisplatin (4) · Gemcitabine (4) · Magnetic Resonance Spectroscopy (4) · Specimen Handling (3) · pembrolizumab (3) · Cystectomy (2) · Cystoscopy (2) · Disulfides (2) · Immunoglobulin G (2) · Nivolumab (2) · Radiation (2) · enfortumab vedotin (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Blood Specimen Collection (1) · Carboplatin (1)
National Cancer Institute (NCI) (2) · Brigham and Women's Hospital (1) · Fox Chase Cancer Center (1) · IRCCS San Raffaele (1) · Matthew Galsky (1) · NRG Oncology (1) · OHSU Knight Cancer Institute (1) · Paradigm Health (1) · University of Washington (1) · Varian, a Siemens Healthineers Company (1) · Yung NA (1)
United States (10) · Canada (2) · Hong Kong (1) · Italy (1)
Alexander Kutikov, M.D. (1) · Brian Baumann, MD (1) · Francesco Montorsi, MD (1) · Jen-Jane Liu (1) · Jonathan Wright, MD (1) · Leslie Ballas (1) · Matthew D Galsky (1) · Matthew Galsky, MD (1) · Scott E Delacroix (1) · Yung Na, PHD (1)
U10CA180821 (1), U10CA180868 (1), U10CA180888 (1)